BioXcel Therapeutics, Inc. - 8-K Filing

BioXcel Therapeutics files Chapter 11 bankruptcy in Delaware and enters a $57.5M stalking horse asset purchase agreement with Teva. (Items: 1.03 of this Current Report on Form 8-K is incorporated herein by reference)

SEC EDGAR ·

Tickers: $BTAI

Read the full article at SEC EDGAR

More Regulatory news